Table 3.
Characteristics of the study patients in the ROR investigation subcohort (n = 30)
| Characteristic | |
|---|---|
| Patients in study, n | 30 |
| Age at surgery, yrs mean (SD) | 66 (9.3) |
| Median follow-up, months (range) | 31 (2–50) |
| FIGO* Stage, n (%) | |
| Stage 1 | 2 (6,7%) |
| Stage 2 | 4 (14%) |
| Stage 3 | 17 (56%) |
| Stage 4 | 7(23,3%) |
| Histology, n (%) | |
| Serous | 22(73,3%) |
| Endometroid | 2 (6,7%) |
| Papillar | 2 (6,7%) |
| Mucinous | 2 (6,7%) |
| Carcinosarcoma | 1 (3,3%) |
| Transitional cell | 1 (3,3%) |
| Grade†, n (%) | |
| Grade 1 and 2 | 8 (26,7%) |
| Grade 3 | 22 (73,3%) |
| Response to platinum therapy‡, n (%) | |
| Sensitive | 20 (66,7%) |
| Resistant | 10 (33,3%) |
| Recurrence | 20 (66,7%) |
| Death | 9 (30%) |
*
FIGO = International Federation of Gynecology.
†
Grade – Grade 3 represents high grade tumors, Grade 1 and 2 low grade tumors.
‡
Sensitivity defined as relapse or event-free follow up time> 12 months after completion of platinum based 1st line therapy.